{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-212358","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.154071+00:00","generated_at":"2026-06-11T10:01:23.187657+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alaunos Therapeutics winds down TCR-T trial, cuts workforce 60%, explores strategic alternatives","bullets":["Q2 2023 net loss $8.8M ($0.04 per share); cash $18.3M, expected to fund ops into Q4 2023.","Wind-down of TCR-T Library Phase 1/2 trial; 83% disease control rate in 6 evaluable patients.","Workforce reduction of ~60%; retains key hunTR platform R&D capabilities.","Engaged Cantor Fitzgerald to explore strategic alternatives including sale, merger, or partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-212358","json":"https://secwatch.observer/filing/0001193125-23-212358.json","markdown":"https://secwatch.observer/filing/0001193125-23-212358.md","text":"https://secwatch.observer/filing/0001193125-23-212358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523212358/0001193125-23-212358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523212358/d467190d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:01:23.187657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4bd9b4db4b984b9e6fb7899598d3c39f7cbcb689","claim":"Alaunos Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $8.8 million, or $(0.04) per share, EPS $(0.04) per share.","evidence_excerpt":"On August 14, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the three and six months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523212358/0001193125-23-212358-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $8.8 million, or $(0.04) per share"},{"label":"EPS","value":"$(0.04) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}